Skip to content
CompoundSci
All peptides
Research vial labelled P-21, a Cognitive peptide studied in preclinical and clinical literature

P-21

The file here is mostly preclinical work plus clinic and community practice, not registrational trials.

A small-molecule neurogenic peptide from Alzheimer's model work. Human data does not exist yet.

General profile

Class
Cognitive
Evidence
Early or preclinical only
Studied dose range
100–200 mcg
Frequency in protocols
Daily
Route
Subcutaneous or intranasal
Half life
Short
Reconstitution
2 mL bacteriostatic water per 5 mg vial
Storage
Refrigerated, ~30 days

Timing and cycling in the literature

Usually dosed in the morning window

Daily

Alerting in the available animal work, so late dosing tends to be reported as sleep disrupting.

Reported cycle: 4 weeks on, 4 weeks off

Neurogenesis work in animal models runs multi-week courses. There is no human protocol to copy.

Watch for: Insomnia when dosed late, and irritability.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Hard stopBody level hard stop

    P-21 + Methylene blue and any serotonergic drug

    Do not run with methylene blue or serotonergic medication

    Methylene blue inhibits MAO-A. Stacked with serotonin-raising agents (SSRIs, SNRIs, MAOIs, tricyclics, tramadol, St John's Wort) the risk is serotonin syndrome. Timing does not fix this one, it is a mechanism conflict.

  • Pick oneRedundant, pick one

    P-21 + Semax

    Same target hit twice

    Overlapping Semax-family signalling. Introduce one, hold it, then judge.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how P-21 fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed human efficacy trial that establishes a dose for the use people are chasing.

Open questions: Treat published dosing as observed practice, not a validated protocol.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature